A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: carbon-11, imaging, PET/CT, sarcosine, scan | Leave a comment »
Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: CureTalk, imaging, Westphalen | Leave a comment »
As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: director, imaging, prostate | 1 Comment »
Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: Axumin, imaging, PET, scan, [18F]fluciclovine | 4 Comments »
The question of how much better the varied, new forms of imaging will be in the evaluation of patients with higher-risk prostate cancer both before and after their treatment is a currently “hot topic” in the world of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: choline-C11, gallium-68, imaging, PET/CT, scan, test | 1 Comment »
Researchers at the University of California San Diego have developed a new kind of MRI called restriction spectrum imaging MRI or just RSI-MRI that seems to discriminate among Gleason grades 3, 4, and 5 with unmatched geographic precision. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: imaging, restriction, RSI, RSI-MRI, spectrum | 7 Comments »
Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, imaging, recurrence | 6 Comments »
